Sugi Predict

Sugi Predict / Compounds / SCHEMBL23326642

SCHEMBL23326642

SCHEMBL23326642

Cn1c(=O)c(N)cc2c(Cl)ncnc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 2/20 0.35
▸ SRC P12931 2/20 0.35
▸ FGFR1 P11362 1/20 0.35
▸ FGFR2 P21802 1/20 0.35
▸ FGFR4 P22455 1/20 0.35
▸ FGFR3 P22607 1/20 0.35
▸ CYP1A2 P05177 3/20 0.33
▸ TSHR P16473 2/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ SLC22A12 Q96S37 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CLK4 Q9HAZ1 1/20 0.33
▸ PI4KA P42356 1/20 0.33
▸ PI4K2B Q8TCG2 1/20 0.33
▸ PI4K2A Q9BTU6 1/20 0.33
▸ PI4KB Q9UBF8 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ LRRK2 Q5S007 1/20 0.33
▸ HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29861884 1.00 EGFR (0.35) EGFRSRCFGFR1FGFR2FGFR4
SCHEMBL29861403 0.81 HSD17B10 (0.33) CYP1A2TSHRHSD17B10CYP2C9SLC22A12
SCHEMBL23326744 0.81 HSD17B10 (0.33) CYP1A2TSHRHSD17B10CYP2C9SLC22A12
SCHEMBL24672007 0.81 SLC22A12 (0.39) SRCCYP1A2TSHRHSD17B10CYP2C9
SCHEMBL23326542 0.77 TLR7 (0.36) EGFRSRCFGFR1FGFR2FGFR4
SCHEMBL29910281 0.77 TLR7 (0.36) EGFRSRCFGFR1FGFR2FGFR4
SCHEMBL29861603 0.76 CYP1A2 (0.38) CYP1A2TSHRCYP2C9CYP3A4HPGD
SCHEMBL23326451 0.76 CYP1A2 (0.38) CYP1A2TSHRCYP2C9CYP3A4HPGD
SCHEMBL12410481 0.74 SELE (0.35) SRCHSD17B10SLC22A12PI4KAPI4K2B
SCHEMBL17148436 0.73 SELE (0.34) SRCSLC22A12PI4KAPI4K2BPI4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4620531-A2 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. (US) 2025-09-24 — — EP disclosed
US-12258366-B2 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2025-03-25 — — US disclosed
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-11-16 — — US disclosed
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-11-16 — — US disclosed
EP-4055017-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. (US) 2022-09-14 — — EP disclosed
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2021-11-09 — — US disclosed
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2021-05-13 — — US disclosed
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2021-05-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof SOS1, SOST, SOS2 EGFR 1530/4885SRC 282/4885FGFR1 917/4885
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 EGFR 1567/4885SRC 428/4885FGFR1 2011/4885
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 EGFR 1567/4885SRC 428/4885FGFR1 2011/4885
US-12258366-B2 Bicyclic heteroaryl compounds and uses thereof SOST, SOS1, SOS2 EGFR 1567/4885SRC 428/4885FGFR1 2011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.